An Overview of Bioactive 1,3-Oxazole-Containing Alkaloids from Marine Organisms
Pharmaceuticals, 2021 1,3-Oxazole chemicals are a unique class of five-membered monocyclic heteroarenes, containing a nitrogen atom and an oxygen. These alkaloids have attracted extensive attention from medicinal chemists and pharmacologists owing to their diverse arrays of ...
Jinyun Chen +5 more
doaj +1 more source
Treatment for non-tuberculous mycobacteria: challenges and prospects. [PDF]
Front MicrobiolNon-Tuberculous mycobacteria (NTM) are opportunistic environmental bacteria. Globally, NTM incidence is increasing and modeling suggests that, without new interventions, numbers will continue to rise.
Conyers LE, Saunders BM.
europepmc +3 more sources
MDR Tuberculosis Treatment [PDF]
, 2022 MDR; Tratamiento; TuberculosisMDR; Tractament; TuberculosiMDR; Treatment; TuberculosisMultidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic ...
Aznar, Maria Luisa +4 more
core +2 more sources
Drug Repurposing for Tuberculosis [PDF]
, 2021 Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a major global health concern given the increase in multiple forms of drug-resistant TB. This underscores the importance of a continuous pipeline of new anti-TB agents.
Cardoso, Nicole C. +3 more
core +2 more sources
Protein targets in Mycobacterium tuberculosis and their inhibitors for therapeutic implications: A narrative review [PDF]
, 2023 Advancement in the area of anti-tubercular drug development has been full-fledged, yet, a very less number of drug molecules have reached phase II clinical trials, and therefore "End-TB" is still a global challenge.
Nagarajan, U, Natarajan, S, Sreelatha, S
core +4 more sources
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis:a 2023 TBnet/RESIST-TB consensus statement [PDF]
, 2023 Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis
core +4 more sources
Challenges and recent progress in drug discovery for tropical diseases [PDF]
, 2018 Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people.
A Guidi +117 more
core +2 more sources
Comparison of In Vitro Activity and MIC Distributions between the Novel Oxazolidinone Delpazolid and Linezolid against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis in China. [PDF]
Antimicrob Agents Chemother, 2018 ABSTRACT Oxazolidinones are efficacious in treating mycobacterial infections, including tuberculosis (TB) caused by drug-resistant Mycobacterium tuberculosis . In this study, we compared the in vitro activities and MIC distributions of delpazolid, a novel oxazolidinone, and ...
Zong Z +9 more
europepmc +4 more sources
Bridging science and policy in tuberculosis treatment through innovations in precision medicine, drug development, and cohort research: a narrative review. [PDF]
Ewha Med JRecent advancements in tuberculosis treatment research emphasize innovative strategies that enhance treatment efficacy, reduce adverse effects, and adhere to patient-centered care principles. As tuberculosis remains a significant global health challenge,
Min J, Andrade BB, Kim JS, Jeong Y.
europepmc +3 more sources
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic [PDF]
, 2021 The WHO 2020 global TB Report estimates that in 2019 there were an estimated 500,000 cases of multi-drug resistant TB (MDR-TB) of which only 186,772 MDR-TB cases were diagnosed, and positive treatment outcomes were achieved in 57% of them.
Galvin, J +5 more
core